Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Pari Pharma Gmbh

Bayer Schering Pharma Ag

Meiji Seika Pharma Co., Ltd.

Insmed Incorporated

Adverio Pharma Gmbh

Bayer Schering Pharma Aktiengellschaft

Michael Hahn

Johannes-Peter Stasch

Frank Wunder

Andreas Knorr

Karl-Heinz Schlemmer

Eva-Maria Becker

Volkhart Min-Jian Li

Friederike Stoll

Thomas Lampe

Dieter Lang

Martina Delbeck

Markus Follmann

Walter Hübsch

Claudia Hirth-Dietrich

Udo Albus

Klemens Lustig

Elke Stahl

Sherif El Sheikh

Elisabeth Woltering

Doris Gehring

Björn Rosenstein

Thomas Rölle

Thomas Ernst Müller

Wahed Ahmed Moradi

Hanna Tinel

Niels Lindner

Stephan Bartel

Michael Härter

Eva Maria Becker-Pelster

Ildiko Terebesi

Philipp Holzmann

Harald Schulz

Alexandros Vakalopoulos

Joachim Mittendorf

Joerg Keldenich

Dirk Schneider

Dominique Mutschmann

Karl Collins

René Martin

Janine Nicolai

Moritz Beck-Broichsitter

Eva-Maria Becker-Pelster

Nils Griebenow

Heinrich Meier

Stefan Heitmeier

Klaus Münter

Peter Sandner

Luisella Toschi

Johanna Mosig

Masashi Tanaka

Peter Fey

Peter Kolkhof

Gorden Redlich

Josef Pernerstorfer

Vladimir Malinin

Britta Olenik

Heiko Schirmer

Cristina Alonso-Alija

Manfred Keller

Stefan Weigand

Lisa Dietz

Walter Perkins

Birgit Keil

Georges Von Degenfeld

Sascha Roeder

Brian S Miller

Christian Pilger

Xingong Li

Guido Becker

Julian Egger

Clemens Bothe

Philipp Kroneberg

Johanna Anlahr

Kuniko Shoji

Nao Sano

Roman Egle

Annett Richter

Carola Fuchs

Helene Faber

Thomas Müller

Bernd Rösler

Matthias Finke

Dehe Duan

Jianfei Yang

Denghui Chen

Dominique Seidel

Yukihiro Yagi

Toshie Sugano

Andŕeas Knorr

Edgard Osswald

Björn Eschrich

Ingo Schraut

Johannes Nagelschmitz

Soundos Saleh

Tobias Mundry

Gerrit Weimann

David Jung

Mark Parry

The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 μg, preferably 480 to 2000 μg of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably in form of monohydrate I of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid in form of mono hydrate (II) of formula (I-M-II), is administered to a patient in need thereof once or twice daily for a period of at least two consecutive days, preferably at least 2 to 7 consecutive days, preferably for a period of at least 14 consecutive days, in particular from after onset of treatment for the whole course of the disease, wherein the inhalative dosage form preferably comprises the combination of the active ingredient and a pharmaceutically suitable excipient or carrier, while preferably the active ingredient and a pharmaceutically suitable excipient are filled in a hard capsule.

Treatment of cardiopulmonary disorders

An aerosol generator for generating an aerosol from a fluid, comprising: a vibratable membrane having a first side for being in contact with the fluid and an opposite second side, the membrane having a plurality of through holes penetrating the membrane in an extension direction from the first side to the second side, whereby the fluid passes the through holes from the first side to the second side when the membrane is vibrated for generating the aerosol at the second side, each through hole having along its extension direction a smallest diameter, a larger diameter that is larger than the smallest diameter and defined by that diameter that is closest to triple, preferably twice said smallest diameter, each through hole having a nozzle portion defined by that continuous portion of the through hole in the extension direction comprising the smallest diameter of the through hole and bordered by the larger diameter of the through hole, wherein the ratio of the total length of each through hole in the extension direction to the length of a respective one of said nozzle portions in the extension direction is at least 4, preferably at least 4.5 and most preferred equal to or larger than 5.

Aerosol generator

The present invention relates to a control device for controlling an operation of an aerosol nebulizer system (), said aerosol nebulizer system () comprising an aerosol generator () for nebulizing a liquid and a plurality of sensor units (), said control device () comprising: a communication unit (), configured to establish a wireless communication connection and to perform data transmission with the aerosol nebulizer system (), a sensor data control unit (), configured to trigger a selection of sensor data related to the sensor units () to be wirelessly transmitted to the control device ().

Control device for aerosol nebulizer system

The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

Branched 3-phenylpropionic acid derivatives and their use

The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle. 

Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors

The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders

The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same

The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.

SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

5-aminotetrahydroquinoline-2-carboxylic acids and their use

Growing community of inventors

Langenfeld, Germany

Michael Hahn